Fig 2. Molecular structure of compounds ethyl 7-acetyl-3-benzoyl-2-methyl-indolizine-1-carboxylate (3), ethyl 7-acetyl-3-benzoyl-2-ethyl-indolizine-1-carboxylate (4), ethyl 7-acetyl-3-(4-chlorobenzoyl)-2-ethyl-indolizine-1-carboxylate (5), and diethyl 3-(4-fluorobenzoyl)indolizine-1,2-dicarboxylate (6) for their anti-TB activity against MDR strains of MTB [10].